Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCI-186 QT/QTc Interval Study in Healthy Subjects
NCT04029090Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of edaravone (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Change From Baseline in QTcF With Placebo Adjustment at Cmax of MCI-186. Started Sep 2018; status: completed.
02
Drugs
edaravone
Beyond the preview
Go deeper on NCT04029090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029090.